January 19, 2022 -- PhenoVista Biosciences announced that it has secured funding from BroadOak Capital Partners. The investment will be used to develop new complex products, such as models of the blood-brain barrier and platforms to better understand neurodegenerative diseases, according to the company.
PhenoVista Biosciences provides customized imaging-based phenotypic assay services. It has developed assays for small and large biotechnology and pharmaceutical companies, as well as government agencies. To date, it has developed over 100 different phenotypic assays.